Henry Schein Beheer

Beheer criteriumcontroles 2/4

De CEO Henry Schein is Stan Bergman, benoemd in Jan1989, heeft een ambtstermijn van 35.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.01M, bestaande uit 16.2% salaris en 83.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.6% van de aandelen van het bedrijf, ter waarde R$ 330.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 12.3 jaar.

Belangrijke informatie

Stan Bergman

Algemeen directeur

US$10.0m

Totale compensatie

Percentage CEO-salaris	16.2%
Dienstverband CEO	35.8yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	12.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Stan Bergman's beloning veranderd ten opzichte van Henry Schein's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 28 2024	n/a	n/a	US$314m
Jun 29 2024	n/a	n/a	US$352m
Mar 30 2024	n/a	n/a	US$388m
Dec 30 2023	US$10m	US$2m	US$416m
Sep 30 2023	n/a	n/a	US$445m
Jul 01 2023	n/a	n/a	US$458m
Apr 01 2023	n/a	n/a	US$478m
Dec 31 2022	US$8m	US$2m	US$538m
Sep 24 2022	n/a	n/a	US$638m
Jun 25 2022	n/a	n/a	US$650m
Mar 26 2022	n/a	n/a	US$646m
Dec 25 2021	US$11m	US$2m	US$631m
Sep 25 2021	n/a	n/a	US$626m
Jun 26 2021	n/a	n/a	US$606m
Mar 27 2021	n/a	n/a	US$438m
Dec 26 2020	US$6m	US$751k	US$403m
Sep 26 2020	n/a	n/a	US$591m
Jun 27 2020	n/a	n/a	US$585m
Mar 28 2020	n/a	n/a	US$713m
Dec 28 2019	US$14m	US$1m	US$701m
Sep 28 2019	n/a	n/a	US$488m
Jun 29 2019	n/a	n/a	US$444m
Mar 30 2019	n/a	n/a	US$438m
Dec 29 2018	n/a	n/a	US$431m
Sep 29 2018	n/a	n/a	US$304m
Jun 30 2018	n/a	n/a	US$352m
Mar 31 2018	n/a	n/a	US$377m

Compensatie versus markt: De totale vergoeding ($USD 10.01M ) Stan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 2.40M ).

Compensatie versus inkomsten: De beloning van Stan is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Stan Bergman (74 yo)

35.8yrs

Tenure

US$10,005,729

Compensatie

Mr. Stanley M. Bergman, also known as Stan, has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989 and has been its Executive Director since 1982. Mr. Bergman served a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stanley Bergman	Executive Chairman & CEO	35.8yrs	US$10.01m	0.60% R$ 330.8m
James Breslawski	President	19.5yrs	US$2.69m	0.11% R$ 62.8m
Ronald South	Senior VP & CFO	2.6yrs	US$2.35m	0.0080% R$ 4.4m
Michael Ettinger	Executive VP & COO	2.3yrs	US$2.97m	0.071% R$ 39.0m
Mark Mlotek	Executive VP	12.8yrs	US$3.22m	0.075% R$ 41.3m
Olga Timoshkina	VP of Corporate Finance	3.2yrs	geen gegevens	geen gegevens
Christopher Pendergast	Senior VP & CTO	6.6yrs	geen gegevens	geen gegevens
Graham Stanley	VP of Investor Relations & Strategic Finance Project Officer	no data	geen gegevens	geen gegevens
Walter Siegel	Senior VP & Chief Legal Officer	11.1yrs	geen gegevens	0.032% R$ 17.4m
Ann Gothard	Vice President of Global Corporate Media Relations	no data	geen gegevens	geen gegevens
Christine Sheehy	Senior VP & Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Gerard Meuchner	Chief Global Communications Officer & VP	12.8yrs	geen gegevens	geen gegevens

8.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van H1SI34 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stanley Bergman	Executive Chairman & CEO	42.8yrs	US$10.01m	0.60% R$ 330.8m
Mark Mlotek	Executive VP	29.2yrs	US$3.22m	0.075% R$ 41.3m
Philip Laskawy	Independent Lead Director	22.8yrs	US$335.40k	0.029% R$ 16.1m
Joseph Herring	Independent Director	8.5yrs	US$313.00k	0.018% R$ 9.8m
Louis Sullivan	Chairman of Medical Advisory Board	18.3yrs	US$280.70k	geen gegevens
Norman Matthews	Member of Medical Advisory Board	no data	US$277.40k	geen gegevens
Bradley Sheares	Independent Director	14.8yrs	US$304.20k	0.0027% R$ 1.5m
Carol Raphael	Independent Director	12.3yrs	US$282.60k	0.023% R$ 12.9m
Kurt Kuehn	Independent Director	8.5yrs	US$316.40k	0.0014% R$ 772.1k
Deborah Derby	Independent Director	3.8yrs	US$304.80k	0.00061% R$ 334.0k
Mohamad Ali	Independent Director	3.8yrs	US$271.60k	0.0061% R$ 3.3m
Anne Margulies	Independent Director	6.4yrs	US$291.40k	0.016% R$ 8.6m

12.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van H1SI34 zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.3 jaar).

Henry Schein Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Henry Schein Appoints Carole T. Faig as New Independent Director

Recent updates

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire Acentus.

Ananym Capital Management Pushes for Changes at Henry Schein

Ananym Capital Management Pushes for Changes at Henry Schein

Henry Schein, Inc. Updates Earnings Guidance for the Full Year 2024

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from FTSE All-World Index (USD)

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd